Gwendolyn Wu is a reporter at BioPharma Dive. She focuses on biotech startups, venture capital, and the healthcare ecosystem, with a particular emphasis on pharmaceuticals and medical specialties. Gwendolyn's work has been featured in notable publications including the Houston Chronicle, San Francisco Chronicle, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Gwendolyn Wu's coverage primarily revolves around the biotechnology industry, particularly focusing on press releases and private sector announcements. She is likely to be interested in pitches related to groundbreaking developments in biotech, such as new drug approvals, IPO filings, or significant funding rounds.
Given her focus on business (16%) within the context of biotechnology (45%), she may also be receptive to news about mergers and acquisitions involving biotech companies or innovative business strategies within the industry.
As Gwendolyn does not have a specific geographic focus mentioned, it is likely that she covers global developments in the field of biotechnology. Therefore, international perspectives and stories with broad relevance are more likely to resonate with her reporting interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.
The British biotechnology startup is making "pan-gamma deltaā T cell engagers it says can address the limitations of similar, existing therapies.
By: Gwendolyn Wu
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings.
By: Gwendolyn Wu
The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.
By: Gwendolyn Wu
This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
By: Gwendolyn Wu
The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem āmore competitiveā and steering dollars away from āhalf-baked ideas.ā
By: Gwendolyn Wu
Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.
